Prevention of mother to child transmission of HIV: evaluation of a pilot programme in a district hospital in rural Zimbabwe
- 11 November 2004
- Vol. 329 (7475), 1147-1150
- https://doi.org/10.1136/bmj.329.7475.1147
Abstract
Problem Zimbabwe has one of the highest rates of HIV seroprevalence in the world. In 2001 only 4% of women and children in need of services for prevention of mother to child transmission of HIV were receiving them. Design Pilot implementation of the first programme for prevention of mother to child transmission of HIV in rural Zimbabwe. Setting 120 bed district hospital in Buhera district (285 000 inhabitants), Manicaland, Zimbabwe. Key measures for improvement Programme uptake indicators monitored for 18 months; impact of policy evaluated by assessing up-scaling of programme. Strategies for change Voluntary counselling and testing services for HIV were provided in the hospital antenatal clinic. Women identified as HIV positive and informed of their serostatus and their newborn were offered a single dose antiretroviral treatment of nevirapine; mother-child pairs were followed up through routine health services. Nursing staff and social workers were trained, and community mobilisation was conducted. Effects of change No services for prevention of mother to child transmission of HIV were available at baseline. Within 18 months, 2298 pregnant women had received pretest counselling, and the acceptance of HIV testing reached 93.0%. Of all 2137 women who had an HIV test, 1588 (74.3%) returned to collect their result; 326 of the 437 HIV positive women diagnosed had post-test counselling, and 104 (24%) mother-child pairs received nevirapine prophylaxis. Lessons learnt Minimum staffing, an enhanced training programme, and involvement of district health authorities are needed for the implementation and successful integration of services for prevention of mother to child transmission of HIV. Voluntary counselling and testing services are important entry points for HIV prevention and care and for referral to community networks and medical HIV care services. A district approach is critical to extend programmes for prevention of mother to child transmission of HIV in rural settings. The lessons learnt from this pilot programme have contributed to the design of the national expansion strategy for prevention of mother to child transmission of HIV in Zimbabwe.Keywords
This publication has 16 references indexed in Scilit:
- Diagnosis of paediatric HIV infection in a primary health care setting with a clinical algorithm.2004
- Preventing Mother-to-Child HIV Transmission in a Developing CountryJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Nevirapine to prevent mother-to-child transmission of HIV-1 among women of unknown serostatusThe Lancet, 2003
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trialThe Lancet, 2003
- Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, ZambiaAIDS, 2003
- A Multicenter Randomized Controlled Trial of Nevirapine Versus a Combination of Zidovudine and Lamivudine to Reduce Intrapartum and Early Postpartum Mother‐to‐Child Transmission of Human Immunodeficiency Virus Type 1The Journal of Infectious Diseases, 2003
- MTCT-Plus Program Has Two Goals: End Maternal HIV Transmission + Treat MothersJAMA, 2002
- HIV-1/AIDS and maternal and child health in AfricaThe Lancet, 2002
- Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trialThe Lancet, 2002
- 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trialThe Lancet, 1999